Published in N Engl J Med on June 13, 2013
Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol (2014) 1.04
SALL4 is a new target in endometrial cancer. Oncogene (2013) 1.02
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 0.97
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 0.95
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 0.94
Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma. J Immunol Res (2014) 0.93
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 0.92
Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer (2015) 0.92
Hippo signaling influences HNF4A and FOXA2 enhancer switching during hepatocyte differentiation. Cell Rep (2014) 0.88
SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer. PLoS One (2015) 0.87
Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer (2015) 0.86
Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner. Exp Hematol (2014) 0.85
SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma. Oncotarget (2015) 0.84
Sall4-Gli3 system in early limb progenitors is essential for the development of limb skeletal elements. Proc Natl Acad Sci U S A (2015) 0.83
The nucleosome remodeling and deacetylase complex in development and disease. Transl Res (2014) 0.83
Sall4 in "stemness"-driven hepatocarcinogenesis. N Engl J Med (2013) 0.83
SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis. J Pathol Transl Med (2015) 0.82
Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma. Springerplus (2014) 0.81
Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. J Hematol Oncol (2013) 0.80
Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts. Neoplasia (2014) 0.80
SALL4, the missing link between stem cells, development and cancer. Gene (2016) 0.80
Liver cancer: SALL4--a cancer marker and target. Nat Rev Clin Oncol (2013) 0.79
MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4. Oncotarget (2016) 0.79
Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a meta‑analysis of individual studies. Oncotarget (2016) 0.79
Cancer: Importance of oncofetal gene, SALL4, in a subset of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 0.78
Recent advances in bioinformatics reveal the molecular heterogeneity of hepatocellular carcinoma. Liver Cancer (2014) 0.78
Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.78
Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma. Ann Surg Treat Res (2016) 0.78
Developmental Stage-Specific Hepatocytes Induce Maturation of HepG2 Cells by Rebuilding the Regulatory Circuit. Mol Med (2015) 0.78
Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases. Hum Pathol (2014) 0.77
Nuclear localization of SALL4: a stemness transcription factor. Cell Cycle (2014) 0.77
The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus. Virchows Arch (2016) 0.76
Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol (2015) 0.76
The next new target in leukemia: The embryonic stem cell gene SALL4. Mol Cell Oncol (2015) 0.76
Stem cell gene SALL4 in aggressive hepatocellular carcinoma: a cancer stem cell-specific target? Hepatology (2014) 0.76
Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis. Oncotarget (2017) 0.75
DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection. Oncogene (2016) 0.75
The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma. Stem Cells Int (2016) 0.75
Characteristics of hepatocellular carcinoma with stem/progenitor cell phenotypes. Gastroenterology (2013) 0.75
Cell Cycle M-phase Genes are Highly Upregulated in Anaplastic Thyroid Carcinoma. Thyroid (2016) 0.75
A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy. Oncotarget (2016) 0.75
The evolving concept of liver cancer stem cells. Mol Cancer (2017) 0.75
SALL4 promotes gastric cancer progression through activating CD44 expression. Oncogenesis (2016) 0.75
Knockdown of Sall4 inhibits intrahepatic cholangiocarcinoma cell migration and invasion in ICC-9810 cells. Onco Targets Ther (2016) 0.75
Targeting SALL4 by entinostat in lung cancer. Oncotarget (2016) 0.75
SALLuting a new biomarker in hepatocellular carcinoma. Ann Hepatol (2014) 0.75
The Recent Advances on Liver Cancer Stem Cells: Biomarkers, Separation, and Therapy. Anal Cell Pathol (Amst) (2017) 0.75
Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells. Oncol Lett (2017) 0.75
High-throughput flow cytometry screening of human hepatocellular carcinoma reveals CD146 to be a novel marker of tumor-initiating cells. Biochem Biophys Rep (2016) 0.75
Developmental Stage-Specific Embryonic Induction of HepG2 Cell Differentiation. Dig Dis Sci (2015) 0.75
Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem (1990) 9.21
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood (2006) 2.53
Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs (2009) 2.38
Murine inner cell mass-derived lineages depend on Sall4 function. Proc Natl Acad Sci U S A (2006) 2.35
Differential roles of Sall4 isoforms in embryonic stem cell pluripotency. Mol Cell Biol (2010) 1.88
Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82
A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PLoS One (2010) 1.79
Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. Ann Thorac Surg (2006) 1.79
Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex. PLoS One (2009) 1.77
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology (2013) 1.63
SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. Cancer (2009) 1.59
Regulation and function of Spalt proteins during animal development. Int J Dev Biol (2009) 1.58
Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. Gastroenterology (2008) 1.53
Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol (2006) 1.50
SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int J Oncol (2011) 1.47
Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. Am J Surg Pathol (2009) 1.37
Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood (2013) 1.15
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol (2006) 4.81
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol (2007) 4.27
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res (2010) 4.06
Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol (2006) 3.98
Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood (2002) 3.97
Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity (2004) 3.84
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
C/EBPbeta is required for 'emergency' granulopoiesis. Nat Immunol (2006) 3.53
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Plasticity of marrow-derived stem cells. Blood (2003) 3.45
A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell (2010) 3.43
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J (2005) 3.23
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg (2013) 3.11
Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet (2006) 2.96
Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell (2008) 2.87
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology (2006) 2.78
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood (2007) 2.77
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res (2005) 2.72
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med (2013) 2.70
Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis (2011) 2.69
Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood (2005) 2.64
The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. Genes Dev (2006) 2.62
Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg (2006) 2.59
Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A (2005) 2.59
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood (2006) 2.53
Hematopoietic chimerism in liver transplantation patients and hematopoietic stem/progenitor cells in adult human liver. Hepatology (2012) 2.47
Tbx3 improves the germ-line competency of induced pluripotent stem cells. Nature (2010) 2.46
T-cell factor 3 regulates embryonic stem cell pluripotency and self-renewal by the transcriptional control of multiple lineage pathways. Stem Cells (2008) 2.43
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
MicroRNA-134 modulates the differentiation of mouse embryonic stem cells, where it causes post-transcriptional attenuation of Nanog and LRH1. Stem Cells (2007) 2.40
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J (2007) 2.34
Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res (2006) 2.32
Transcriptome analysis of zebrafish embryogenesis using microarrays. PLoS Genet (2005) 2.32
11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. J Nucl Med (2013) 2.29
Sall4 regulates distinct transcription circuitries in different blastocyst-derived stem cell lineages. Cell Stem Cell (2008) 2.28
Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood (2009) 2.26
Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat Med (2009) 2.20
Mutations in sodium-borate cotransporter SLC4A11 cause recessive congenital hereditary endothelial dystrophy (CHED2). Nat Genet (2006) 2.20
Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol (2005) 2.19
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet (2007) 2.18
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood (2010) 2.17
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood (2012) 2.12
Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells (2006) 2.11
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood (2004) 2.11
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet (2006) 2.10
MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol (2009) 2.08
A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol (2007) 2.06
Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg (2011) 2.05
DNMT1-interacting RNAs block gene-specific DNA methylation. Nature (2013) 2.04
Identification of local and circulating cancer stem cells in human liver cancer. Hepatology (2008) 2.02
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res (2008) 2.00
Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg (2004) 1.99
Liver resection using a saline-linked radiofrequency dissecting sealer for transection of the liver. J Am Coll Surg (2005) 1.98
Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol (2005) 1.96
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res (2008) 1.95
MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun (2010) 1.92
PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev (2008) 1.90
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell (2013) 1.89
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med (2006) 1.88
Function of the SIRT1 protein deacetylase in cancer. Biotechnol J (2007) 1.88
Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol (2003) 1.88
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol (2008) 1.87
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer (2007) 1.87
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J (2003) 1.85
The national program for deceased organ donation in China. Transplantation (2013) 1.83
Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet (2005) 1.82
Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol (2011) 1.81
A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut (2013) 1.80
Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A (2007) 1.80
A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PLoS One (2010) 1.79